NCT03412955: A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

NCT03412955
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 21 Years to 99 Years åÊ (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with leptomeningeal only disease, without other measurable brain metastasis
https://ClinicalTrials.gov/show/NCT03412955

Comments are closed.

Up ↑